Althea Stillman
Directeur/Membre du Conseil chez Innervace, Inc.
Profil
Althea Stillman is currently a Director at Innervace, Inc. Previously, she worked as a Director at CTx Operations, Inc. She holds a doctorate degree from Yale University and an undergraduate degree from the University of California, Berkeley.
Postes actifs de Althea Stillman
| Sociétés | Poste | Début |
|---|---|---|
Innervace, Inc.
 Innervace, Inc. BiotechnologyHealth Technology Innervace, Inc. is an American regenerative therapy company that develops technology to replace lost connections due to brain degeneration or injury. The company is based in Philadelphia, PA. The company's lead program focuses on mimicking the lost nigrostriatal pathway in patients with Parkinson's disease. The company was founded by Kacy Cullen and Douglas Smith, and the CEO is Nader Halim. | Directeur/Membre du Conseil | - |
Anciens postes connus de Althea Stillman
| Sociétés | Poste | Fin |
|---|---|---|
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | - |
Formation de Althea Stillman
| University of California, Berkeley | Undergraduate Degree |
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Innervace, Inc.
Innervace, Inc. BiotechnologyHealth Technology Innervace, Inc. is an American regenerative therapy company that develops technology to replace lost connections due to brain degeneration or injury. The company is based in Philadelphia, PA. The company's lead program focuses on mimicking the lost nigrostriatal pathway in patients with Parkinson's disease. The company was founded by Kacy Cullen and Douglas Smith, and the CEO is Nader Halim. | Health Technology |
